AZ & DS collaboration with Summit for Datroway

Summary by AI BETAClose X

AstraZeneca and Daiichi Sankyo have entered a clinical collaboration with Summit Therapeutics to evaluate Datopotamab Deruxtecan (Datroway) in combination with Ivonescimab across multiple tumour types, including lung and breast cancers, with a planned Phase III trial in first-line triple-negative breast cancer. This agreement builds on a previous collaboration and an equity investment by AstraZeneca in Summit, aiming to advance combination strategies in cancer treatment. Each company will contribute their respective medicines for the trials, with AstraZeneca or Daiichi Sankyo sponsoring, and all parties sharing trial costs while retaining development and commercial rights to their own medicines.

Disclaimer*

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings